Resistant Bacteria in Children in France

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-01

Study Completion Date

2025-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is observational, multicenter and prospective study for surveillance of the use of new antibiotics in pediatrics for treated pediatrics infections due to multi-resistant bacteria

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Clinical, Genetic and Immunological Factors Involved in the Development of Severe Bacterial Infections in Pediatrics

NCT07111793

Severe Bacterial Infections

NOT_YET_RECRUITING NA

Antibiotic Stewardship to Prevent Early Sepsis in Preterm Infants

NCT06930911

Prematurity, Infections

ACTIVE_NOT_RECRUITING

Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus

NCT02701608

Infective Endocarditis

UNKNOWN PHASE3

Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus

NCT02701595

Infective Endocarditis

UNKNOWN PHASE3

Discontinuation of Antibiotic Susceptibility Testing on Enterococcus Faecalis Positive Urine Cultures in Hospitalized Patients: an Impact on Antibiotic Prescriptions? (FaecaCible)

NCT05743192

Antibiotic Susceptibility Reporting

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main of this study is to evaluate the relevance of prescribing "new antibiotics" according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation

As this is a surveillance study, the clinical and biological characteristics of the children included will be described.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infection Due to Resistant Bacteria Multi-antibiotic Resistance Antibiotic Prescription Risk Factors Healing Complications Intensive Care Unit Hospital Discharge Outcome, Fatal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children under 18 years of age
* Hospitalized in France in a hospital center working with the ACTIV/GPIP network
* Treated with one or more of the following antibiotics:

* Colimycin (Colistimethate sodium)
* Cefiderocol
* Aztreonam in combination
* Ceftolozane-Tazobactam
* Ceftazidime-avibactam
* Meropenem/vaborbactam
* Imipenem/Relebactam
* Tigecycline
* Daptomycin
* Ceftaroline fosamil
* Tedizolid phosphate
* Fidaxomicin
* Ceftobiprole
* Dalbavancin

In association with a documented infection performed by:

* Blood culture
* Normally sterile site

* Cerebrospinal fluid
* Pleural fluid
* Pleura
* Peritoneum
* Joint fluid
* Other
* Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000)
* Respiratory specimens if the bacteria was considered responsible for the infection
* Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),....

* Related to colonization with multidrug-resistant bacteria without documentation.